Respiratory syncytial virus immunization program for the United States: Impact of performance determinants of a theoretical vaccine

Highlights • An RSV vaccine would substantially reduce inpatient hospitalizations and outpatient visits even if the effectiveness is 50%. • Appropriate endpoints should be chosen to show full medical and economic value. • Endpoints impacting death and hospitalization are the most important to collec...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2013-09, Vol.31 (40), p.4347-4354
Main Author: REGNIER, Stephane A
Format: Article
Language:English
Subjects:
Allergy and Immunology
Antibodies, Monoclonal, Humanized - therapeutic use
Antiviral Agents - therapeutic use
Applied microbiology
Biological and medical sciences
Child, Preschool
children
Clinical endpoints
complications (disease)
Cost-Benefit Analysis
Cost-effectiveness
Delivery of Health Care - economics
disease control
economic costs
Economic impact
economic valuation
Economics
Emergency medical care
Fundamental and applied biological sciences. Psychology
half life
Health care
health services
Hospitalization
Hospitals
Humans
immunity
Immunization
Immunization Programs - economics
income
Infant
Infant Mortality
Infant, Newborn
Infants
Microbiology
Models, Theoretical
neonates
Palivizumab
Prophylaxis
quality-adjusted life year
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - drug therapy
Respiratory Syncytial Virus Infections - economics
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus Vaccines - economics
Respiratory Syncytial Virus Vaccines - therapeutic use
Respiratory Syncytial Virus, Human - immunology
risk
RSV
United States
vaccination
vaccine development
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Value drivers
viruses
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • An RSV vaccine would substantially reduce inpatient hospitalizations and outpatient visits even if the effectiveness is 50%. • Appropriate endpoints should be chosen to show full medical and economic value. • Endpoints impacting death and hospitalization are the most important to collect. • Duration and month of onset of protective immunity affect vaccine impact.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2013.07.024